Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss

American Journal of Surgical Pathology

Volumn 39, Issue 1, 2015, Pages 52-60

  Singh, Naveena ^a   Leen, Sarah L ^a   Han, Guangming ^b   Faruqi, Asma ^a   Kokka, Fani ^a   Rosenthal, Adam ^c   Jiang, Xin Rong ^d   Kim, Rachel ^d   McAlpine, Jessica N ^d   Blake Gilks, C ^d  

^a Division of Cellular Pathology Barts Health   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Differentiated vulvar intraepithelial neoplasia; Dvin; HPV independent vulvar squamous cell carcinoma; P53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOPSY; CANADA; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; CLINICAL TRIAL; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PAPILLOMA VIRUS; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TEACHING HOSPITAL; TREATMENT OUTCOME; TUMOR INVASION; UNITED KINGDOM; VERY ELDERLY; VIROLOGY; VULVAR NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BRITISH COLUMBIA; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FEMALE; HOSPITALS, TEACHING; HUMANS; IMMUNOHISTOCHEMISTRY; LONDON; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VULVAR NEOPLASMS;

EID: 84919361213     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000291     Document Type: Article

References (36)

1. Ueda Y, Enomoto T, Kimura T, et al. Two distinct pathways to development of squamous cell carcinoma of the vulva. J Skin Cancer. 2011;2011:951250.
2. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013;62:161-175.
3. Toki T, Kurman RJ, Park JS, et al. Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. Int J Gynecol Pathol. 1991;10:107-125.
4. Chiesa-Vottero A, Dvoretsky PM, Hart WR. Histopathologic study of thin vulvar squamous cell carcinomas and associated cutaneous lesions: a correlative study of 48 tumors in 44 patients with analysis of adjacent vulvar intraepithelial neoplasia types and lichen sclerosus. Am J Surg Pathol. 2006;30:310-318.
5. McCluggage WG. Recent developments in vulvovaginal pathology. Histopathology. 2009;54:156-173.
6. Kokka F, Singh N, Faruqi A, et al. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus- negative vulval squamous cell carcinoma? Int J Gynecol Cancer. 2011;21:1297-1305.
7. Reyes MC, Cooper K. An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. J Clin Pathol. 2014;67:290-294.
8. Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am J Surg Pathol. 2000;24:429-441.
9. Maclean AB. Vulval cancer: prevention and screening. Best Pract Res Clin Obstet Gynaecol. 2006;20:379-395.
10. van der Avoort IA, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol. 2006;25: 22-29.
11. Abell MR. Intraepithelial carcinomas of epidermis and squamous mucosa of vulva and perineum. Surg Clin North Am. 1965;45: 1179-1198.
12. van de Nieuwenhof HP, Bulten J, Hollema H, et al. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. Mod Pathol. 2011;24:297-305.
13. van den Einden LC, de Hullu JA, Massuger LF, et al. Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia. Mod Pathol. 2013;26:874-880.
14. Choschzick M, Hantaredja W, Tennstedt P, et al. Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol. 2011;30: 497-504.
15. Rosenthal AN, Hopster D, Ryan A, et al. Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. Br J Cancer. 2003;88:251-256.
16. Soufir N, Queille S, Liboutet M, et al. Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors. Br J Dermatol. 2007;156:448-453.
17. Lassus H, Leminen A, Lundin J, et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91:504-512.
18. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222:191-198.
19. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol. 2004;23:129-137.
20. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248-1253.
21. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32:76-115.
22. Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol. 1995; 85(pt 1):709-715.
23. Eva LJ, Ganesan R, Chan KK, et al. Vulval squamous cell carcinoma occurring on a background of differentiated vulval intraepithelial neoplasia is more likely to recur: a review of 154 cases. J Reprod Med. 2008;53:397-401.
24. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009;45:851-856.
25. van de Nieuwenhof HP, van Kempen LC, de Hullu JA, et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol Biomarkers Prev. 2009;18:2061-2067.
26. Lindell G, Nasman A, Jonsson C, et al. Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. Gynecol Oncol. 2010;117:312-316.
27. Alonso I, Fuste V, del Pino M, et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol Oncol. 2011;122:509-514.
28. Ordi J, Alejo M, Fuste V, et al. HPV-negative vulvar intraepithelial neoplasia (VIN) with basaloid histologic pattern: an unrecognized variant of simplex (differentiated) VIN. Am J Surg Pathol. 2009;33: 1659-1665.
29. Mannweiler S, Sygulla S, Winter E, et al. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J Am Acad Dermatol. 2013; 69:73-81.
30. Nascimento AF, Granter SR, Cviko A, et al. Vulvar acanthosis with altered differentiation: a precursor to verrucous carcinoma? Am J Surg Pathol. 2004;28:638-643.
31. Crum CP, McKeon FD, Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer. 2012;22(suppl 1):S29-S34.
32. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49-56.
33. Pinto AP, Miron A, Yassin Y, et al. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. Mod Pathol. 2010;23: 404-412.
34. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
35. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22:1071-1077.
36. Gunia S, Koch S, Jain A, et al. Does the width of the surgical margin of safety or premalignant dermatoses at the negative surgical margin affect outcome in surgically treated penile cancer? J Clin Pathol. 2014;67:268-271.